| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Otto Cars | |
| Sara K Olofsson | |||
| P2860 | cites work | Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis | Q28344614 |
| Muller's ratchet decreases fitness of a DNA-based microbe | Q33588611 | ||
| The biological cost of antibiotic resistance | Q33745219 | ||
| In vitro selective antibiotic concentrations of beta-lactams for penicillin-resistant Streptococcus pneumoniae populations | Q33747544 | ||
| Concentration-dependent selection of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance | Q33980535 | ||
| Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. | Q33981343 | ||
| Fitness cost of chromosomal drug resistance-conferring mutations | Q34107494 | ||
| Mutator bacteria as a risk factor in treatment of infectious diseases | Q34113782 | ||
| An elevated mutation frequency favors development of vancomycin resistance in Staphylococcus aureus | Q34142416 | ||
| Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. | Q34307105 | ||
| Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies | Q34347864 | ||
| Antimicrobial drug use and resistance among respiratory pathogens in the community | Q34347901 | ||
| Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence | Q34467495 | ||
| Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model | Q34820573 | ||
| Stretching the mutant prevention concentration (MPC) beyond its limits | Q35115526 | ||
| The mutant selection window and antimicrobial resistance | Q35153856 | ||
| Biological costs and mechanisms of fosfomycin resistance in Escherichia coli | Q35685710 | ||
| Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis | Q35810298 | ||
| Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection | Q35818681 | ||
| Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin | Q35847429 | ||
| Virulence of antibiotic-resistant Salmonella typhimurium | Q36013861 | ||
| Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. | Q36048167 | ||
| Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update | Q36072639 | ||
| Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs | Q36220885 | ||
| Hypermutable bacteria isolated from humans--a critical analysis | Q36583214 | ||
| Mutant selection window hypothesis updated. | Q36728061 | ||
| Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates | Q37568953 | ||
| Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo i | Q37733597 | ||
| Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model | Q39731788 | ||
| In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. | Q39746394 | ||
| Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model | Q39792565 | ||
| Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance | Q39828366 | ||
| Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance | Q40359740 | ||
| Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli | Q40666822 | ||
| Low correlation between MIC and mutant prevention concentration | Q42943040 | ||
| Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus | Q43579575 | ||
| Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia | Q43908420 | ||
| Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance | Q44144059 | ||
| Fitness of antibiotic resistant Staphylococcus epidermidis assessed by competition on the skin of human volunteers | Q44514658 | ||
| Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing | Q44570717 | ||
| The effects of oral and intramuscular administration and dose escalation of enrofloxacin on the selection of quinolone resistance among Salmonella and coliforms in pigs | Q44586225 | ||
| Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori | Q44588558 | ||
| Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli | Q44624656 | ||
| In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model | Q45003097 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium tuberculosis. | Q48063219 | ||
| The dynamic structure of EF-G studied by fusidic acid resistance and internal revertants | Q50138974 | ||
| The mutant selection window in rabbits infected with Staphylococcus aureus. | Q51109317 | ||
| Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone. | Q51203486 | ||
| Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. | Q54147489 | ||
| Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. | Q54466642 | ||
| Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. | Q54518615 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibiotic resistance | Q380775 |
| P304 | page(s) | S129-36 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Optimizing drug exposure to minimize selection of antibiotic resistance | |
| P478 | volume | 45 Suppl 2 |
| Q28478851 | "One-size-fits-all"? Optimizing treatment duration for bacterial infections |
| Q40039262 | Acute myeloid leukemia and the infectious diseases consultant |
| Q64448298 | Adaptation Through Lifestyle Switching Sculpts the Fitness Landscape of Evolving Populations: Implications for the Selection of Drug-Resistant Bacteria at Low Drug Pressures |
| Q38814607 | Adaptive resistance to antibiotics in bacteria: a systems biology perspective |
| Q39629148 | Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae. |
| Q33876556 | Antibiotic dose impact on resistance selection in the community: a mathematical model of beta-lactams and Streptococcus pneumoniae dynamics |
| Q33870110 | Antimicrobial drug use in food-producing animals and associated human health risks: what, and how strong, is the evidence? |
| Q26753831 | Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction |
| Q62788758 | Assessing evolutionary risks of resistance for new antimicrobial therapies |
| Q33925668 | Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort study. |
| Q49567812 | Bacterial sepsis : Diagnostics and calculated antibiotic therapy |
| Q49589601 | Bacterial sepsis : Diagnostics and calculated antibiotic therapy |
| Q52590950 | Beyond dose: Pulsed antibiotic treatment schedules can maintain individual benefit while reducing resistance. |
| Q26829707 | Can we prevent antimicrobial resistance by using antimicrobials better? |
| Q28727500 | Cancer in light of experimental evolution |
| Q64133725 | Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli |
| Q92424667 | Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China |
| Q34104262 | Ciprofloxacin dosage and emergence of resistance in human commensal bacteria |
| Q39044604 | Determination of minimum biofilm eradication concentrations of orbifloxacin for canine bacterial uropathogens over different treatment periods |
| Q90446999 | Development, optimization, standardization, and validation of a simple in-house agar gradient method to determine minimum inhibitory concentration of vancomycin for Staphylococcus aureus |
| Q42673180 | Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis |
| Q28552950 | Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance? |
| Q33667581 | Emergence and spread of antibiotic resistance: setting a parameter space. |
| Q37125014 | Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis. |
| Q42275774 | Evaluation of anti-infective potential of a tribal folklore Odina wodier Roxb against some selected microbes and herpes simplex virus associated with skin infection |
| Q39974195 | Evolution of glyphosate resistance in a Lolium rigidum population by glyphosate selection at sublethal doses. |
| Q64265666 | Evolutionary epidemiology models to predict the dynamics of antibiotic resistance |
| Q34987675 | Expert review of the evidence base for self-therapy of travelers' diarrhea |
| Q51792293 | Exploring the reasons why pharmacists dispense antibiotics without prescriptions in Khartoum state, Sudan. |
| Q91811717 | Five rules for resistance management in the antibiotic apocalypse, a road map for integrated microbial management |
| Q49667957 | Fosfomycin efficacy and emergence of resistance among Enterobacteriaceae in an in vitro dynamic bladder infection model. |
| Q48948199 | Human Lysozyme Synergistically Enhances Bactericidal Dynamics and Lowers the Resistant Mutant Prevention Concentration for Metronidazole to Helicobacter pylori by Increasing Cell Permeability. |
| Q55398494 | Identification of a Novel Polyamine Scaffold With Potent Efflux Pump Inhibition Activity Toward Multi-Drug Resistant Bacterial Pathogens. |
| Q34783696 | Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance |
| Q28551361 | Integrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs. Adaptive Treatment |
| Q35750265 | Integration of PK/PD for dose optimization of Cefquinome against Staphylococcus aureus causing septicemia in cattle |
| Q35826386 | Is selection relevant in the evolutionary emergence of drug resistance? |
| Q91614255 | Measuring Appropriate Antibiotic Prescribing in Acute Hospitals: Development of a National Audit Tool Through a Delphi Consensus |
| Q30911044 | Mutant prevention concentration, pharmacokinetic-pharmacodynamic integration, and modeling of enrofloxacin data established in diseased buffalo calves |
| Q42022178 | Perturbation of iron homeostasis promotes the evolution of antibiotic resistance. |
| Q26825326 | Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer |
| Q37586452 | Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance |
| Q38375170 | Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial |
| Q37849394 | Population biological principles of drug-resistance evolution in infectious diseases |
| Q40096314 | Postantibiotic Effect and Postantibiotic Sub-MIC Effect of LTX-109 and mupirocin on Staphylococcus aureus Blood Isolates |
| Q91063940 | Quality control programmes for veterinary antimicrobial medicines |
| Q36137477 | Residues of chlortetracycline, doxycycline and sulfadiazine-trimethoprim in intestinal content and feces of pigs due to cross-contamination of feed |
| Q34921154 | Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions |
| Q40906422 | Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery |
| Q30239019 | Screening and treating Helicobacter pylori infection for gastric cancer prevention on the population level |
| Q40238353 | Studying the effect of administration route and treatment dose on the selection of enrofloxacin resistance in commensal Escherichia coli in broilers. |
| Q91782965 | Suppression of bacteriocin resistance using live, heterospecific competitors |
| Q41648730 | Testing the mutant selection window hypothesis in vitro and in vivo with Staphylococcus aureus exposed to fosfomycin |
| Q92688670 | The Effect of Expert Feedback on Antibiotic Prescribing in Pediatrics: Experimental Evidence |
| Q51033406 | The path of least resistance: aggressive or moderate treatment? |
| Q36256381 | Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication |
| Q60936240 | Use of C-reactive protein to tailor antibiotic use: a systematic review and meta-analysis |
| Q40499211 | Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study |
| Q21145725 | When the most potent combination of antibiotics selects for the greatest bacterial load: the smile-frown transition |
| Q84230576 | [Musculoskeletal infections in the era of multiresistant pathogens] |
Search more.